Knowledge, Attitudes, and Practices of European Healthcare Professionals towards Hepatitis A and Hepatitis B Vaccination in at-Risk Adults

Author:

Shamarina Dasha1ORCID,Sluga-O’Callaghan Martina2,Kassianos George34,Marijam Alen1,Dave Vaidehi5,Davenport Eric5,Andani Anar1,Curran Desmond1,Dewda Pavitra1,Steffen Robert67ORCID

Affiliation:

1. GSK, 1300 Wavre, Belgium

2. RTI Health Solutions, 69009 Lyon, France

3. Royal College of General Practitioners, London NW1 2FB, UK

4. British Global & Travel Health Association, London BA1 2SA, UK

5. RTI Health Solutions, Research Triangle Park, Durham, NC 27709, USA

6. WHO Collaborating Centre for Travellers’ Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, CH-8001 Zurich, Switzerland

7. Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas, Houston, TX 77030, USA

Abstract

Despite the occurrence of several hepatitis A (hepA) and hepatitis B (hepB) outbreaks in Europe in the last few decades, not all European countries have implemented hepA and hepB vaccinations in their national immunization programs, especially for adults at risk for hepA and/or hepB infection, such as men who have sex with men or patients with chronic liver disease. Currently, little is known on the attitudes of European healthcare professionals (HCPs) towards hepA and hepB vaccinations for at-risk adults. We conducted an online survey among HCPs in Germany, Spain, and the United Kingdom to assess their awareness of and adherence to their national hepA and hepB vaccination guidelines for at-risk adults. Among the 698 HCPs who took the survey, most (91.1%) were familiar with their national vaccination recommendations and always followed them or followed them most of the time when advising or prescribing hepA or hepB vaccines. Major and moderate barriers for recommending or administering such vaccines were the non-disclosure of risk factors by the patient (53.0–57.6%) and the patient’s lack of motivation or knowledge about the risk of the disease (50.3–52.9%). These results may help inform strategies to improve and accelerate hepA and hepB vaccination in European at-risk adults.

Funder

GlaxoSmithKline Biologicals SA

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference43 articles.

1. UK Health Security Agency (2023, May 05). Hepatitis A: The Green Book, Chapter 17, Available online: https://www.gov.uk/government/publications/hepatitis-a-the-green-book-chapter-17.

2. UK Health Security Agency (2023, May 05). Hepatitis B: The Green Book, Chapter 18, Available online: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18.

3. Migueres, M., Lhomme, S., and Izopet, J. (2021). Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. Viruses, 13.

4. World Health Organization (2023, May 05). Hepatitis A. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a.

5. Hepatitis A in the era of vaccination;Wasley;Epidemiol. Rev.,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3